ArticleMolecular microbiology2014
Evaluation of the kinetics and mechanism of action of anti-integration host factor-mediated disruption of bacterial biofilms.
Article in Molecular microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 81 citations in OpenAlex.
- Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- The natural human adaptive IgG-specific immune response is skewed towards non-protective tail domains of DNABII proteins.Frontiers in immunology · 2026Article
- Respiratory tract antimicrobial peptides more effectively killed multiple methicillin-resistantMicrobiology spectrum · 2025Article
- An engineered peptide derived from the innate immune effector high-mobility group box 1 disrupts and prevents dual-genera biofilms formed by common respiratory tract pathogens.FEMS microbiology letters · 2025Article
- Multimodal evaluation of drug antibacterial activity reveals cinnamaldehyde analog anti-biofilm effects againstBiofilm · 2024Article
- Oral and middle ear delivery of otitis media standard of care antibiotics, but not biofilm-targeted antibodies, alter chinchilla nasopharyngeal and fecal microbiomes.NPJ biofilms and microbiomes · 2024Article
- Beyond the double helix: the multifaceted landscape of extracellular DNA inFrontiers in cellular and infection microbiology · 2024Review
- The Respiratory Microbiome in Paediatric Chronic Wet Cough: What Is Known and Future Directions.Journal of clinical medicine · 2023Review
- Disruption of nontuberculous mycobacteria biofilms induces a highly vulnerable to antibiotic killing phenotype.Biofilm · 2023Article
- Nontypeable Haemophilus influenzae released from biofilm residence by monoclonal antibody directed against a biofilm matrix component display a vulnerable phenotype.Scientific reports · 2023Article
- ESKAPEE pathogens newly released from biofilm residence by a targeted monoclonal are sensitized to killing by traditional antibiotics.Frontiers in microbiology · 2023Article
- Monoclonal antibodies that target extracellular DNABII proteins or the type IV pilus of nontypeableBiofilm · 2022Article
- Antibiofilm agents with therapeutic potential against enteroaggregative Escherichia coli.PLoS neglected tropical diseases · 2022Article
- Current treatments for biofilm-associated periprosthetic joint infection and new potential strategies.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2022Review
- Effects of Extracellular Self- and Nonself-DNA on the Freshwater MicroalgaPlants (Basel, Switzerland) · 2022Article
- A Humanized Monoclonal Antibody Potentiates Killing of Diverse Biofilm-Forming Respiratory Tract Pathogens by Antibiotics.Antimicrobial agents and chemotherapy · 2022Article
- Bacterial Biofilms Utilize an Underlying Extracellular DNA Matrix Structure That Can Be Targeted for Biofilm Resolution.Microorganisms · 2022Review
- Crumbling the Castle: Targeting DNABII Proteins for Collapsing Bacterial Biofilms as a Therapeutic Approach to Treat Disease and Combat Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2022Article
- Human monoclonal antibodies againsteLife · 2022Article
- Bacterial nucleoid-associated protein HU as an extracellular player in host-pathogen interaction.Frontiers in cellular and infection microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
The extracellular polymeric substance produced by many human pathogens during biofilm formation often contains extracellular DNA (eDNA). Strands of bacterial eDNA within the biofilm matrix can occur in a lattice-like network wherein a member of the DNABII family of DNA-binding proteins is positioned at the vertex of each crossed strand. To date, treatment of all biofilms tested with antibodies directed against one DNABII protein, Integration Host Factor (IHF), results in significant disruption. Here, using non-typeable Haemophilus influenzae as a model organism, we report that this effect was rapid, IHF-specific and mediated by binding of transiently dissociated IHF by anti-IHF even when physically separated from the biofilm by a nucleopore membrane. Further, biofilm disruption fostered killing of resident bacteria by previously ineffective antibiotics. We propose the mechanism of action to be the sequestration of IHF upon dissociation from the biofilm eDNA, forcing an equilibrium shift and ultimately, collapse of the biofilm. Further, antibodies against a peptide positioned at the DNA-binding tips of IHF were as effective as antibodies directed against the native protein. As incorporating eDNA and associated DNABII proteins is a common strategy for biofilms formed by multiple human pathogens, this novel therapeutic approach is likely to have broad utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.